Linda Duska

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial”.

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30180-7

N/A

5.1DataRank · unranked

233 citations

Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle +19 more

A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6010

N/A

0.510DataRank · unranked

29 citations

Daniela Matei, Panagiotis A. Konstantinopoulos, Matthew S. Block, Andrea Jewell, Stéphanie Gaillard +15 more

A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5514

N/A

0.470DataRank · unranked

22 citations

Husam Alqaisi, David E. Cohn, Jing‐Yi Chern, Linda Duska, Andrea Jewell +15 more

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4618

N/A

0.464DataRank · unranked

21 citations

Virginia L. Filiaci, Joan L. Walker, Laura L. Holman, Emily K. Hill, Richard G. Moore +13 more

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.04.016

N/A

0DataRank · unranked

19 citations

Kathleen N. Moore, Leigh A. Cantrell, Britt Erickson, Linda Duska, Debra L. Richardson +10 more

Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.03.027

N/A

0DataRank · unranked

20 citations

Danielle Enserro, Matthew S. Block, Steven Waggoner, Linda Duska, Andrea E. Wahner-Hendrickson +11 more